Humaid Al-Shamsi, The Chairman of Nexomic, CEO of Burjeel Cancer Institute (BCI) Comprehensive Cancer Center, shared on LinkedIn:
“Nexomic is pleased to announce Prof. Khaled Musallam as a member of its Advisory Board.
His internationally recognised expertise in rare blood disorders, global clinical trials, real-world evidence and novel therapy development will strengthen Nexomic’s work in evidence generation and help translate AI-driven discoveries into meaningful patient outcomes.”
Other articles featuring Khaled Musallam on OncoDaily.
